Sanofi to Acquire Origimm Biotechnology
- Date: 02-Dec-2021
- Source: Nasdaq
- Sector:Economy
- Country:Middle East
Sanofi to Acquire Origimm Biotechnology
Healthcare company Sanofi S.A. (SNY) recently revealed that it has entered into an agreement to acquire a biotechnology company, Origimm Biotechnology GmbH. The terms of the deal have not been disclosed so far. Following the news, shares of the company rose 1% to close at $48.06 on Wednesday.
Origimm’s expertise in the discovery of virulent skin microbiome components and antigens from bacteria causing skin disease will allow Sanofi to gain a strong foothold in this space.
The buyout will enable Sanofi to add ORI-001 to its early-stage pipeline. ORI-001 is a therapeutic vaccine candidate for acne vulgaris based on recombinant proteins, which entered preliminary clinical studies in the third quarter of 2021.
Select Sector 
Select Country 
